GGrantIndex
← Search

Senior Leadership

$52,326P30FY2011CANIH

Beckman Research Institute/City Of Hope, Duarte CA

Investigators

Linked publications, trials & patents

Trial NCT07664670Trial NCT07664579Trial NCT07650656Trial NCT07628894Trial NCT07619599Trial NCT07612085Trial NCT07611370Trial NCT07608627Trial NCT07608458Trial NCT07608445Trial NCT07595874Trial NCT07590583Trial NCT07583810Trial NCT07583303Trial NCT07582172Trial NCT07582159Trial NCT07578077Trial NCT07578025Trial NCT07544992Trial NCT07365306Trial NCT07363408Trial NCT07293403Trial NCT07288034Trial NCT07278856Trial NCT07275216Trial NCT07271355Trial NCT07235501Trial NCT07226544Trial NCT07226102Trial NCT07225855Trial NCT07225738Trial NCT07220447Trial NCT07219147Trial NCT07218913Trial NCT07218718Trial NCT07218692Trial NCT07218510Trial NCT07210086Trial NCT07202247Trial NCT07184294Trial NCT07136493Trial NCT07133997Trial NCT07128680Trial NCT07126301Trial NCT07125729Trial NCT07042438Trial NCT07040982Trial NCT07037004Trial NCT07025564Trial NCT07025538Trial NCT07020533Trial NCT07003100Trial NCT06996119Trial NCT06985784Trial NCT06954831Trial NCT06922604Trial NCT06918431Trial NCT06910761Trial NCT06860815Trial NCT06859008Trial NCT06834126Trial NCT06815029Trial NCT06815003Trial NCT06780787Trial NCT06763341Trial NCT06763328Trial NCT06735690Trial NCT06735664Trial NCT06731894Trial NCT06675136Trial NCT06675123Trial NCT06672224Trial NCT06626256Trial NCT06625619Trial NCT06581211Trial NCT06580015Trial NCT06575725Trial NCT06575686Trial NCT06575296Trial NCT06572631Trial NCT06572618Trial NCT06572605Trial NCT06549478Trial NCT06543381Trial NCT06538389Trial NCT06500377Trial NCT06498973Trial NCT06454409Trial NCT06454383Trial NCT06453044Trial NCT06447987Trial NCT06440850Trial NCT06408220Trial NCT06399419Trial NCT06328621Trial NCT06287944Trial NCT06260033Trial NCT06249282Trial NCT06196008Trial NCT06195891

Abstract

SENIOR LEADERSHIP Since the previous review, there has been significant recruitment and promotion of key individuals to senior leadership positions to expand the Cancer Center leadership from five positions (Director and four Associate Directors) to eight. The Center Director, Theodore Krontiris, MD, PhD, in his capacity as Center Director and as Executive Vice President for Medical and Scientific Affairs of City of Hope, is the chief means by which all organizational entities and inherent capabilities are integrated in the research of the Cancer Center. As EVPMSA, he oversees the derivation and renewal of the Institutional strategic plan. Through his collaboration with, and oversight of, the COH Beckman Research Institute (BRI) Director and the COH National Medical Center (NMC) Chief Medical Officer, he assures that faculty hiring in the BRI and NMC, respectively, conforms to the strategic plan and is consonant with needs of the Cancer Center Programs[unreadable]for expanding their interdisciplinary research activities, as well as addressing peer-review and external advisors'recommendations about the state of the Center. The Deputy Director, Richard Jove, PhD, recruited from H. Lee Moffitt Cancer Center, has substantial experience in leading translational research programs. He oversees the implementation of the overall Center strategy and has scientific oversight of Shared Resources. The AD for Administration, Michael Benedict, PharmD, oversees all office operations and CCSG management, and has administrative oversight of Shared Resources. Robert Figlin, MD, AD for Clinical Research, was recently recruited from UCLA. He oversees all clinical cancer activities and the coordination of all cancer clinical trials. Yun Yen, MD, PhD, is the AD for Translational Research, a new leadership position since the previous review. He is responsible for integrating correlative laboratory studies into clinical trials. In addition, Drs. Yen and Figlin co-chair the Task Force for Cancer Center Disease Program Development (see Essential Characteristics), which includes the Deputy Director and the other ADs as members. Smita Bhatia, MD, a national leader in cancer survivorship studies, was promoted to AD for Population Research and is responsible for developing research directions in cancer prevention and control. John Rossi, PhD, is a longtime leader in RNA biology and continues to foster successful interdisciplinary collaborations within the Cancer Center membership as part of his role as AD for Basic Research. Joyce Niland, PhD, with her outstanding experience in medical informatics, was appointed AD for Information Sciences, a new AD position concomitant with the increasing role of informatics in Cancer Center operations. In addition to the qualifications and roles of each of the Senior Leadership positions described on the following pages, many of these Cancer Center leaders are Division Chairs or Department Directors within BRI or NMC.

View original record on NIH RePORTER →